Enliven Therapeutics (ELVN) Stock Forecast: StockMap's 2-Week Call
ELVN stock forecast: StockMap's model leans Underperform on Enliven Therapeutics for the two weeks after the Nov 19 close, toward ELVN trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on ELVN since Oct 5; by chance, a call on the same dates was right 46% of the time.
Enliven Therapeutics last closed at $46.41, +3.39% on the session.
Against the IVW growth benchmark the position is +5.72% over the forecast window.
Enliven Therapeutics' market cap is $3.42B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where ELVN sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
9 daily calls for ELVN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Enliven Therapeutics in the 28th percentile on return on equity, where 100 is best.
Enliven Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Enliven Therapeutics as the 33rd largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Enliven Therapeutics ranks 53rd of 153 in the group, against a group median of -0.36.